High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding | The Motley Fool
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.

Source: The Motley Fool
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.